Psoriasis: Treatment and Novel Approaches
Psoriasis is chronic inflammatory disease of the immune system that mostly affects the skin and joints, but also may affect the fingernails, the toenails, and the inside of the mouth. In the United States it affects as many as 7.5 million Americans and 125 million people worldwide according to the World Psoriasis Day consortium. Join Frank Narjes, a Principal Scientist at AstraZeneca as he discusses Psoriasis from a MedChem perspective, highlighting a novel orally bioavailable treatment of this prevalent autoimmune disease with the discovery of clinical candidate AZD0284. In this presentation he will prove that by inhibiting the function of the pro-inflammatory cytokine IL-17 or blockage of its receptor with antibodies positive results can be found in the clinic for diseases such as psoriasis, ankylosing spondylitis and rheumatoid arthritis.
What You Will Learn
- Importance of structure-based design
- Use of early dose-to-man predictions to assess compound quality
- Implementation of a robust cell assay in primary human cells linked to effect in clinic
The Fine Print
ACS Webinars® does not endorse any products or services. The views expressed in this presentation are those of the presenters and do not necessarily reflect the views or policies of the American Chemical Society.
Benefits of Membership
- ACS Webinars Archive: Every one of our 200+ past webinars available on demand
- Save Money: Members receive discounts on meetings, development courses and more!
- Access to SciFinder®: Members receive 25 complimentary SciFinder® research activities per year